What is the appropriate cyclosporine dosing for a 22 kg child with atopic dermatitis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 20, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Cyclosporine Dosing for 22 kg Child with Atopic Dermatitis

For a 22 kg child with atopic dermatitis, start cyclosporine at 2.5-5 mg/kg/day (55-110 mg/day total), divided into two daily doses, with the higher end (5 mg/kg/day = 110 mg/day) reserved for severe disease requiring rapid control. 1

Dosing Strategy

The most recent AAD pediatric guidelines 1 specify:

  • Starting dose range: 2.5-5 mg/kg/day
  • For your 22 kg patient: 55-110 mg daily
  • Divide into twice-daily dosing (e.g., 27.5 mg BID at lower dose or 55 mg BID at higher dose)
  • Start at the higher end (5 mg/kg/day) when rapid control is needed for severe disease
  • Start at the lower end (2.5 mg/kg/day) when time is less critical, then increase if inadequate response after 1 month

The British guidelines 2 corroborate this approach, emphasizing that doses below 2.5 mg/kg/day are inadequate for initial control, though they may work for maintenance.

Titration and Duration

Initial phase:

  • Once control is achieved, decrease gradually by 0.5-1 mg/kg steps to find the lowest effective dose 1, 2
  • If starting at 2.5 mg/kg/day shows insufficient improvement after 1 month, increase the dose 2
  • Maximum dose should not exceed 5 mg/kg/day (110 mg/day for this child)

Treatment duration:

  • Generally limited to 1 year 1
  • Short courses of 6 months are preferred when possible 2
  • Research shows longer courses (mean 10.9 months) may reduce relapse risk compared to shorter courses 3
  • The British guidelines 2 confirm cyclosporine is effective and well-tolerated in children aged 2 years and older for courses of 6 weeks to 1 year

Administration Details

  • Take on empty stomach or before meals 2
  • Available as 25 mg, 50 mg, 100 mg capsules or 100 mg/mL liquid 2
  • For 22 kg child at 2.5 mg/kg/day: Use 25 mg capsule BID (total 50 mg/day) or 27.5 mg BID using liquid
  • For 22 kg child at 5 mg/kg/day: Use 50 mg capsule BID (total 100 mg/day) or 55 mg BID using liquid

Critical Monitoring Requirements

First 2 months:

  • Serum creatinine and blood pressure every 2 weeks 2
  • More frequent if any elevation occurs

After 2 months:

  • Monthly monitoring of creatinine and blood pressure 2
  • Can extend to every 2-3 months once stable after 4 months 2

Action thresholds:

  • If creatinine rises >30% above baseline: repeat within 2 weeks; if sustained, reduce dose 2
  • Discontinue if adequate response not achieved within 6 weeks at maximum dose 2

Evidence Quality

The pediatric evidence is robust 2: trials demonstrate cyclosporine is effective and well-tolerated in children aged 2+ years. Research studies 4, 5 show that even low-dose therapy (2.5 mg/kg/day) achieves clinical improvement in 70-80% of children with severe AD, with significant SCORAD reductions. One study 4 found 4 of 7 responders achieved control at just 2.5 mg/kg/day.

Important Caveats

  • Modified vs non-modified formulations are NOT interchangeable - verify which formulation is dispensed as bioavailability differs 2
  • Cyclosporine is off-label for pediatric AD (FDA-approved only for ages ≥16 years) but widely used with strong guideline support 1, 2
  • Avoid concurrent phototherapy - increases skin cancer risk 2
  • Continue optimized topical therapy alongside cyclosporine to reduce required dose and maintain clearance during taper 2
  • Most patients (96%) eventually discontinue due to limited efficacy or side effects, often transitioning to advanced therapies 6

References

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.